Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
Provided By GlobeNewswire
Last update: Oct 7, 2024
BMF-219 is an investigational oral covalent menin inhibitor developed to regenerate insulin-producing beta cells
REDWOOD CITY, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced the attendance at the 1st Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024), taking place in Singapore, 18-20 November 2024. Data from the company's COVALENT-111 and COVALENT-112 diabetes clinical trials will be featured during a long oral presentation and two short oral presentations.
Read more at globenewswire.com
